Inflammation-targeted delivery of corticosteroids using genetically engineered cellular nanoparticles
使用基因工程细胞纳米颗粒靶向炎症递送皮质类固醇
基本信息
- 批准号:10646914
- 负责人:
- 金额:$ 19.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-02-08 至 2025-01-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdrenal Cortex HormonesAdverse effectsAir SacsAnti-Inflammatory AgentsAntibiotic TherapyAntibioticsArtificial nanoparticlesAttenuatedBacteriaBacterial CountsBacterial PneumoniaBindingBiochemistryBiodistributionBiomimeticsBlood Cell CountBlood CirculationCell Adhesion MoleculesCell membraneCellsCellular MembraneCessation of lifeClinicalCommunitiesDataDendritic CellsDiseaseDrug Delivery SystemsEndothelial CellsEndotoxinsEngineeringFormulationGenetic EngineeringGoalsGram-Positive BacteriaHistologyHospitalsImmuneImmune systemImmunologic AdjuvantsImmunosuppressive AgentsIn VitroInfectionInflammationInflammatoryInflammatory ResponseIntegrin alpha4beta1LeftLigandsLiquid substanceLungLung infectionsMembraneMethodsModelingMolecularMorbidity - disease rateMorphologyMusNanodeliveryNanotechnologyNatureOrganOrgan failureP-selectin ligand proteinPathologicPathologyPatientsPatternPerformancePharmaceutical PreparationsPlayProductionProteinsPseudomonas aeruginosaPulmonary InflammationRoleSafetySerumSiteSourceSteroidsStreptococcus pyogenesSurfaceTherapeutic IndexTimeTreatment EfficacyTreatment Side EffectsVascular Cell Adhesion Molecule-1cell typecellular engineeringcellular targetingcytokinedosagedrug resistant bacteriaeffective therapyefficacy evaluationfabricationhuman diseaseimmune activationimprovedin vivointerestintravenous administrationintravenous injectionmethicillin resistant Staphylococcus aureusmortalitymouse modelnanocarriernanoformulationnanoparticlenanoparticulatenext generationpathogenpreventprotein expressionresponseside effectstandard of caretargeted deliveryzeta potential
项目摘要
PROJECT SUMMARY/ABSTRACT
Bacterial pneumonia causes severe local inflammation in the lungs that can result in serious complications if left
unchecked. While antibiotics are oftentimes an effective treatment, drug-resistant bacteria that do not respond
to the standard of care represent a major threat. Bacteria contain a number of pathogen-associated molecular
patterns that are highly efficient at activating the immune system, and the overproduction of proinflammatory
factors can have deleterious effects such as causing the air sacs within the lungs to become filled with fluid. To
address these negative effects, corticosteroids have been employed as an adjunct therapy in combination with
antibiotic treatment. There is clinical evidence that supplemental anti-inflammatories can reduce patient morbidity
and mortality, and the beneficial effects are the most pronounced in cases of severe disease. Despite their
advantages, steroids are broadly immunosuppressive and cannot be administered at high dosages or over
extended periods of time without side effects. In this proposal, our goal is to employ a genetic engineering
approach for creating a next-generation a cellular nanoparticle (CNP) platform that can specifically target sites
of inflammation. CNPs are an emerging class of nanocarrier that utilize the principles of biomimicry, and they
have demonstrated considerable promise for drug delivery applications. Their fabrication involves the coating of
synthetic nanoparticulate cores with naturally derived cellular membrane, which provides an inherently
multifunctional and multi-antigenic layer of camouflage. We will further advance the CNP concept by genetically
engineering the nanoparticles to express specific membrane-bound targeting proteins. Leveraging the fact that
activated endothelial cells at sites of inflammation upregulate their expression of cell adhesion molecules, CNPs
will be fabricated using cell membrane that has been engineered to express the cognate ligands. Each
inflammation-targeting CNP formulation will be loaded with corticosteroids, delivering the payloads precisely to
where they are most needed. By improving the therapeutic index of these drugs, we hope to prevent the harmful
effects associated with excessive inflammation while reducing any treatment-related side effects. If successful,
this approach could potentially be applied across a wide range of inflammation-driven pathologies.
项目总结/文摘
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ronnie H Fang其他文献
Ronnie H Fang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ronnie H Fang', 18)}}的其他基金
Motorized delivery of bacterial antigens to mucosal barriers to enhance immunity against infection
将细菌抗原机动递送至粘膜屏障以增强抗感染免疫力
- 批准号:
10370989 - 财政年份:2022
- 资助金额:
$ 19.75万 - 项目类别:
Motorized delivery of bacterial antigens to mucosal barriers to enhance immunity against infection
将细菌抗原机动递送至粘膜屏障以增强抗感染免疫力
- 批准号:
10605209 - 财政年份:2022
- 资助金额:
$ 19.75万 - 项目类别:














{{item.name}}会员




